



Att. Docket No.: REG 711A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Mark W. Sleeman et al.

Serial No.: 10/811,170

Group: 1635

Filing Date: March 26, 2004

Examiner: to be assigned

Title: Methods of Treating Diabetes by Blocking VEGF-Mediated Activity

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, P. O. Box 1450, Alexandria, VA 22313-1450.

Loren Hernandez
Loren Hernandez

November 12, 2004

Date

Commissioner for Patents
US Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and a copy of the reference listed therein. The PTO is kindly requested to make of record those references, which may be pertinent to the examination of the above-referenced application.


This Information Disclosure Statement is being filed:

After three months of the file date of the above referenced application, but before the mailing date of any of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under §1.114. Accordingly, no fee is required for the submission.

Fees


There is no fee required for the filing of this Information Disclosure Statement. In the event there is a fee inadvertently omitted, Applicants hereby authorizes the fee to be charge to Deposit Account number 18-0650.

Respectfully submitted

A handwritten signature in cursive script, appearing to read "Valeta Gregg", is written over a horizontal line.

Valeta Gregg
Reg. No. 35,127
Attorney for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400

FORM PTO-1449



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att Docket No. : REG 711A
Serial No. : 10/811,170
Applicant: : Mark W. Sleeman et al.
Date Filed : March 26, 2004
Examiner : to be assigned
Group Art Unit : 1635

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/ Subclass</u>	<u>Translation Yes No</u>
_____	WO 00/75319A	14 Dec. 2000	PCT		
_____	WO 02/060489A	8 Aug. 2002	PCT		

OTHER DOCUMENTS

Examiner
Initials

_____ US Patent Application Publication US 2003/0017977 A1, Xia et al.
(Jan. 23, 2003).

EXAMINER
CONSIDERED


DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400